1. Home
  2. ETON vs HSPO Comparison

ETON vs HSPO Comparison

Compare ETON & HSPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ETON
  • HSPO
  • Stock Information
  • Founded
  • ETON 2017
  • HSPO 2014
  • Country
  • ETON United States
  • HSPO United States
  • Employees
  • ETON N/A
  • HSPO N/A
  • Industry
  • ETON Biotechnology: Pharmaceutical Preparations
  • HSPO Blank Checks
  • Sector
  • ETON Health Care
  • HSPO Finance
  • Exchange
  • ETON Nasdaq
  • HSPO Nasdaq
  • Market Cap
  • ETON 199.5M
  • HSPO 87.7M
  • IPO Year
  • ETON 2018
  • HSPO 2022
  • Fundamental
  • Price
  • ETON $8.82
  • HSPO $11.25
  • Analyst Decision
  • ETON Strong Buy
  • HSPO
  • Analyst Count
  • ETON 3
  • HSPO 0
  • Target Price
  • ETON $12.00
  • HSPO N/A
  • AVG Volume (30 Days)
  • ETON 214.1K
  • HSPO 27.4K
  • Earning Date
  • ETON 11-11-2024
  • HSPO 01-01-0001
  • Dividend Yield
  • ETON N/A
  • HSPO N/A
  • EPS Growth
  • ETON N/A
  • HSPO N/A
  • EPS
  • ETON N/A
  • HSPO 0.33
  • Revenue
  • ETON $31,381,000.00
  • HSPO N/A
  • Revenue This Year
  • ETON $19.61
  • HSPO N/A
  • Revenue Next Year
  • ETON $35.39
  • HSPO N/A
  • P/E Ratio
  • ETON N/A
  • HSPO $34.26
  • Revenue Growth
  • ETON 8.14
  • HSPO N/A
  • 52 Week Low
  • ETON $3.03
  • HSPO $10.60
  • 52 Week High
  • ETON $8.66
  • HSPO $11.25
  • Technical
  • Relative Strength Index (RSI)
  • ETON 76.07
  • HSPO 69.42
  • Support Level
  • ETON $7.58
  • HSPO $11.17
  • Resistance Level
  • ETON $8.66
  • HSPO $11.25
  • Average True Range (ATR)
  • ETON 0.42
  • HSPO 0.00
  • MACD
  • ETON -0.07
  • HSPO 0.00
  • Stochastic Oscillator
  • ETON 91.49
  • HSPO 100.00

About ETON Eton Pharmaceuticals Inc.

Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.

About HSPO Horizon Space Acquisition I Corp.

Horizon Space Acquisition I Corp is a blank check company.

Share on Social Networks: